Split History
LXRX split history picture
Lexicon Pharmaceuticals (LXRX) has 1 split in our LXRX split history database. The split for LXRX took place on May 21, 2015. This was a 1 for 7 reverse split, meaning for each 7 shares of LXRX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split.

When a company such as Lexicon Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the LXRX split history from start to finish, an original position size of 1000 shares would have turned into 142.857142857143 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Lexicon Pharmaceuticals shares, starting with a $10,000 purchase of LXRX, presented on a split-history-adjusted basis factoring in the complete LXRX split history. LXRX split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 06/04/2010
End date: 06/03/2020
Start price/share: $9.73
End price/share: $1.89
Dividends collected/share: $0.00
Total return: -80.58%
Average Annual Total Return: -15.11%
Starting investment: $10,000.00
Ending investment: $1,941.67
Years: 10.01
Lexicon Pharmaceuticals is a biopharmaceutical company. Co. is commercializing XERMELO® (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Co. is developing Zynquista™ (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 2 diabetes. Co. is also developing sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease. Co. is developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. According to our LXRX split history records, Lexicon Pharmaceuticals has had 1 split.
Date Ratio
05/21/20151 for 7
LXRX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

MACK Split History
MBOT Split History
MBVX Split History
MCK Split History
MD Split History
MDCI Split History
MDGL Split History
MDGN Split History
MDT Split History
MDVN Split History

Also explore: LXRX shares outstanding history

The Cushing NextGen Infrastructure Income Fund (SZC)
Teligent, Inc. (TLGT)
Laredo Petroleum, Inc. (LPI)
Global Eagle Entertainment Inc. (ENT)
ToughBuilt Industries, Inc. (TBLT)
Cyclacel Pharmaceuticals, Inc. (CYCC)
Chesapeake Energy Corporation (CHK)
Direxion Daily Gold Miners Index Bull 3X Shares (NUGT)
Direxion Zacks MLP High Income Index Shares (ZMLP)
Direxion Daily Retail Bull 3X Shares (RETL)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

LXRX Insider Buying

LXRX Split History | www.SplitHistory.com | Copyright © 2013 - 2020, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.